ALNY Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.…
Industry Peers
BiotechnologyKey Statistics
About Alnylam Pharmaceuticals (NASDAQ: ALNY)
›
Alnylam Pharmaceuticals (NASDAQ: ALNY) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2,500 employees.
The shares were at 147.82 USD on 19 November 2026, down 66.0% over 52 weeks. Its 52-week range is 146.51 USD to 479.79 USD, and it trades at the bottom of that range.
At a market capitalisation of 19.80B USD, it trades at 7.5 times trailing earnings and 14.9 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 34.5, a discount of 78% for ALNY.
Alnylam Pharmaceuticals reports return on equity of 39.8%, an operating margin of 19.5% and revenue up 16.7% year over year.
It holds more cash than debt, a net cash position of 590.40M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 27 analysts cover the stock, with an average rating of Buy; their mean price target of 284.96 USD is 92.8% above the current price. The next earnings report is expected on 11 February 2027.